Trials / Withdrawn

WithdrawnNCT02069106

Efficacy Study of Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction

An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction in Subjects With Mixed Hyperlipoproteinemia

Status: Withdrawn
Phase: Phase 4
Study type: Interventional
Enrollment: 0 (actual)

Sponsor: Nordic Pharma, USA · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

Pro-Omega LDL reduces low-density lipoprotein cholesterol and triglycerides in subjects with mixed hyperlipoproteinemia.

Conditions

Mixed Hyperlipoproteinemia

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Pro-Omega LDL
OTHER	Placebo

Timeline

Start date: 2014-02-01
Primary completion: 2014-05-01
Completion: 2014-07-01
First posted: 2014-02-21
Last updated: 2015-12-14

Source: ClinicalTrials.gov record NCT02069106. Inclusion in this directory is not an endorsement.